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Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of
AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) pro-
gression. In this study, we perform a comprehensive unbiased characterisation of LNCaP cells
chronically exposed to multiple AR inhibitors (ARI). Combined proteomics and metabolomics
analyses implicate an acquired metabolic phenotype common in ARI-resistant cells and
associated with perturbed glucose and lipid metabolism. To exploit this phenotype, we
delineate a subset of proteins consistently associated with ARI resistance and highlight
mitochondrial 2,4-dienoyl-CoA reductase (DECR1), an auxiliary enzyme of beta-oxidation, as
a clinically relevant biomarker for CRPC. Mechanistically, DECR1 participates in redox
homeostasis by controlling the balance between saturated and unsaturated phospholipids.
DECR1 knockout induces ER stress and sensitises CRPC cells to ferroptosis. In vivo, DECR1
deletion impairs lipid metabolism and reduces CRPC tumour growth, emphasizing the
importance of DECR1 in the development of treatment resistance.
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Prostate cancer is the most common cancer amongst men inthe western world1. Due to its reliance on androgenreceptor (AR) signalling, androgen deprivation therapy
(ADT) has long been the standard of care for advanced disease.
However, although the majority of patients initially respond to
hormonal therapy, they ultimately relapse and progress to a lethal
form of the disease, termed castration-resistant prostate cancer
(CRPC).
Over the last decades, specific AR inhibitors (ARI) have shown
promising effects in the clinic, significantly improving patient
outcomes2. Bicalutamide, a first-generation AR antagonist, has
been successfully used for almost two decades3 before being
progressively replaced by enzalutamide (MDV3100), which dis-
played better in vitro characteristics4 and improved efficacy in
patients5,6. In phase 3 clinical trials, enzalutamide treatment
significantly improved progression-free survival in metastatic7,8,
and non-metastatic CRPC patients9. Apalutamide (ARN-509) is
another novel AR antagonist that recently completed Phase 3
clinical evaluation, significantly reducing the risk of metastasis
formation in men with high risk non-metastatic CRPC10.
Despite initial response to enzalutamide and apalutamide, AR
mutations11–14, gene amplification15, aberrant splicing16 or sig-
nalling bypass17 can all account for resistance to AR-targeted
therapies. Therefore, a better understanding of the adaptive
tumour phenotype following treatment resistance will help to
identify novel therapeutic approaches to tackle AR-proficient
CRPC.
AR signalling critically regulates cellular metabolism in pros-
tate cancer18. Hence, targeting metabolism represents an
appealing option to overcome resistance to AR-targeted therapies.
In comparison to other cancers, prostate cancer displays very
specific metabolic features19 such as an early reliance on mito-
chondrial metabolism rather than glycolysis, although the latter
becomes important as the disease progresses20. Prostate cancer is
also characterised by profound alterations in cholesterol and lipid
metabolism21, highlighted by dysregulation of both fatty acid
synthesis and oxidation pathways. This rewiring of lipid meta-
bolism offers new therapeutic opportunities and has led to the
development of multiple inhibitors, some of which are currently
undergoing clinical trials.
In this study, we use a combination of proteomics and meta-
bolomics to perform an unbiased characterisation of LNCaP-
derived cell lines chronically exposed to long-term bicalutamide,
apalutamide or enzalutamide treatment. We show that long-term
resistance to AR inhibition is sustained by profound changes in
glucose and lipid metabolism. This metabolic rearrangement is
mainly dependent on aberrant AR signalling. In addition, we
identify a protein signature associated with acquired resistance to
ARI. Among the top candidates, 2,4-dienoyl-CoA reductase
(DECR1), a mitochondrial enzyme involved in polyunsaturated
fatty acid (PUFA) degradation, represents a potential therapeutic
target for CRPC. DECR1 deletion in CRPC cells reduces in vitro
proliferation and impairs CRPC tumour growth. Mechanistically,
we show that DECR1-deficient prostate cancer cells accumulate
higher levels of polyunsaturated lipids. This results in a strong ER
stress response and an increased sensitivity to GPX4 inhibition,
and suggests a potential role for DECR1 in the control of redox
homeostasis.
Results
ARI-resistant cells display altered but active AR signalling. To
study resistance to AR inhibition, we characterised CRPC deri-
vatives of LNCaP cells that were chronically cultured in the
presence of three distinct AR inhibitors (ARI), namely bicaluta-
mide (first generation ARI), apalutamide and enzalutamide
(second generation ARI). When compared to parental LNCaP
cells, ARI-resistant cells were larger, and exhibited enhanced
cell–cell contact. ARI-resistant cells also generated larger orga-
noid structures when cultured in 3D matrix (Fig. 1a–c). In con-
trast, ARI-resistant cells proliferated at a slower rate than WT
LNCaP (by ~30, 40 and 50% at 72 h for bicalutamide, enzaluta-
mide and apalutamide resistant cells, respectively, Fig. 1d).
Similar to what is observed in patients, ARI-resistant cells dis-
played cross-resistance among the different inhibitors (Fig. 1e).
Because AR is the direct target of the three inhibitors, we first
sought to evaluate the status of AR signalling in the ARI-resistant
cells. In all three cell lines, expression of full-length AR was
maintained or even increased at both protein and mRNA levels
(Fig. 1f, g). Expression of the ARv7 variant was also assessed.
Bicalutamide-resistant cells displayed a significant increase in
expression of the variant, while apalutamide- and enzalutamide-
resistant cells showed no change or a decrease in the level of
ARv7 (Supplementary Fig. 1a). We then looked at the expression
of two canonical target genes downstream of AR, namely KLK3
and FKBP5. While the expression of KLK3 was strongly reduced
in all the resistant cells, FKBP5 expression was either not affected
or even increased in enzalutamide-resistant cells (Fig. 1f, g).
Interestingly, we observed that AR remained in the nucleus of
ARI-resistant cells (Fig. 1h, Supplementary Fig. 1b), and was still
able to bind the promoter of both target genes (Supplementary
Fig. 1c). Altogether these results suggest AR reprogramming,
rather than inactivation, as a general survival strategy in ARI-
resistant prostate cancer cells.
ARI resistance is associated with changes in cell metabolism.
To decipher the mechanisms associated with treatment resistance,
we characterised the proteome of the parental LNCaP and ARI-
resistant cells, cultured in both 2D and 3D conditions (Supple-
mentary Data 1, Supplementary Fig. 2a, b). In comparison to 2D
culture, culturing cancer cells in a 3D matrix has been proposed
to better mimic the in vivo situation22 and therefore is of interest
in the context of biomarker discovery. We next performed
pathway enrichment analysis to identify pathways commonly
dysregulated in ARI-resistant cells in 2D and 3D cultures.
Interestingly, many metabolic pathways were consistently upre-
gulated in ARI-resistant cells regardless of the culture conditions
(Fig. 2a). Indeed, the top upregulated pathways (FDR < 0.05)
within each comparison included amino acid, fatty acid, glucose,
and glutathione metabolism (Fig. 2a).
Along with exosomal and vesicular proteins, we found that
many proteins upregulated in ARI-resistant cells were localised in
mitochondria (Supplementary Fig. 2c), suggesting that mitochon-
drial metabolism might be a key pathway associated with
treatment resistance. Mitochondria are at the crossroad between
glucose and fatty acid metabolism through the production of
citrate and acetyl-CoA. In line with this hypothesis, ARI-resistant
cells also displayed increased expression of PPARG and PGC1A,
two transcription factors that are crucial for mitochondrial
biogenesis and fatty acid metabolism, and of both isoforms of the
Liver X receptor (NR1H2 and NR1H3), another critical factor
involved in the regulation of lipid homeostasis23 (Supplementary
Fig. 2d).
Resistant cells exhibit rewired glucose and lipid metabolism.
To better understand the metabolic differences between ARI-
resistant and the parental LNCaP cells, we profiled 66 metabolites
and identified 16 molecules that were significantly modulated in
at least two of the three resistant cell lines (Fig. 2b, FC= 1.5).
Intracellular glucose levels were consistently lower in resistant
cells, which contrasted with elevated levels of several glycolytic
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Fig. 1 AR signalling is conserved in ARI-resistant cells. a Representative pictures of WT and ARI-resistant LNCaP cells cultured in 2D conditions.
Scale bar represents 100 µm. b Representative pictures of WT and ARI-resistant LNCaP organoids embedded in Matrigel. Scale bar represents 50 µm.
c Quantification of cell (top panel) and organoid (bottom panel) diameter. d Cell proliferation of WT and ARI-resistant LNCaP cells after 48 and 72 h. Cell
count is normalised to initial number of cells at T0. e Cell proliferation of WT and ARI-resistant LNCaP cells treated for 48 h with different AR inhibitors
(10 µM). Cell count is normalised to non-treated condition. f Western blot analysis of AR, KLK3 and FKBP5 expression in WT and ARI-resistant LNCaP
cells. HSC70 was used as a sample loading control. g RT-qPCR analysis of AR (full length, fl), KLK3 and FKBP5 expression in WT and ARI-resistant LNCaP
cells. CASC3 was used as a normalising control. h Immunofluorescence showing nuclear AR expression in WT and ARI-resistant LNCaP cells. Scale bar
represents 20 µm. c–e, g Data are presented as mean values +/− SD. c, g *p-value < 0.05 using a 1-way ANOVA with a Dunnett’s multiple comparisons
test. d, e *p-value < 0.05 using a 2-way ANOVA with a Tukey’s multiple comparisons test. Source data are provided as a Source Data File.
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intermediates (such as H6P, G3P, DHAP, 2-PG, and PEP). ARI-
resistant cells further displayed elevated expression of the glucose
transporter GLUT1 (Supplementary Fig. 2e). Moreover, inhibi-
tion of glycolysis using 2-deoxyglucose (2-DG) potentiated the
effect of enzalutamide in LNCaP cells (Supplementary Fig. 2f).
Combined with our proteomic data (Fig. 2a), these results suggest
that ARI-resistant cells may undergo a metabolic shift towards
increased glucose consumption. To test this hypothesis, we
cultured the cells for a short period (1 h) in the presence of
[U13C]-glucose and measured the levels of 13C-derived metabo-
lites by mass spectrometry. In line with increased glucose meta-
bolism, substantial enrichment of labelled glycolytic intermediates
was observed in ARI-resistant cells in comparison to WT LNCaP
(Fig. 2c). Levels of labelled pyruvate intermediates remained
elevated in ARI resistant cells at a later timepoint (24 h), con-
firming that glycolysis was more active in the resistant cells
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(Fig. 2d). Interestingly, a significant proportion of the labelled
glucose also served for the generation of glutathione, potentially
pointing at the importance of redox homeostasis in resistant cells
(Fig. 2a, e).
Glycolysis ultimately produces lactate and pyruvate. Pyruvate
can in turn be used in the mitochondria to generate acetyl-coA
and support de novo fatty acid synthesis, a process typically
dysregulated in aggressive prostate cancer21. Therefore, we
incubated cells in [U13C]-glucose for 72 h and traced 13C
incorporation into palmitic, oleic and stearic acid (Fig. 3a and
Supplementary Fig. 3). In all three ARI-resistant cell lines, 13C
enrichment of palmitate, oleate and stearate was significantly
higher than in WT LNCaP cells, indicating increased glucose-
derived de novo fatty acid synthesis in ARI-resistant cells. In
addition, all three resistant lines demonstrated high levels of ACC
and ACLY, two regulatory enzymes of the fatty acid synthesis
(Fig. 3b). To test whether increased levels of glucose-derived fatty
acid synthesis resulted in lipid accumulation in the resistant cells,
we compared the cellular lipid profile of the ARI-resistant cells
and the parental LNCaP. Strikingly, resistance to AR inhibition
was associated with a profound remodelling of the cellular
lipidome. We identified 114 lipid molecules that were signifi-
cantly modulated in all three resistant cell lines, with the majority
of them being upregulated in ARI-resistant cells (Fig. 3c, FC=
1.5). All three resistant cell lines displayed a strong and consistent
accumulation of numerous species of triglycerides (TG), espe-
cially polyunsaturated TG, and sphingolipids (Fig. 3c, right
panel). Multiple ceramides and cardiolipin derivatives were also
enriched in the resistant cell lines, while several classes of
phospholipids, such as phosphatidylcholine (PC) and phospha-
tidylethanolamine (PE) derivatives, were in contrast over-
represented in WT LNCaP (Fig. 3c, left panel).
Altogether, these results support the idea that increased
consumption of glucose in the ARI-resistant cells serves, at least
in part, to support glutathione and de novo fatty acid synthesis.
This metabolic rewiring ultimately leads to lipid accumulation
and major changes in the cellular lipidome of the ARI-
resistant cells.
AR drives metabolic reprogramming in ARI-resistant cells.
AMPK is an important regulator of glucose metabolism, and
targeting AMPK-dependent autophagy has been proposed to
enhance enzalutamide sensitivity24. Therefore, we tested whether
AMPK activation could contribute to the metabolic rewiring
observed in ARI-resistant cells. ARI-resistant cells displayed
increased AMPKα expression and activity, as evidenced by
increased ACC phosphorylation, in comparison to WT LNCaP
cells (Supplementary Fig. 4a). However, silencing of AMPKα
expression (Supplementary Fig. 4b) only marginally reduced the
levels of labelled glycolytic intermediates generated from 13C-
glucose (Supplementary Fig. 4c).
AR has itself been implicated as a key regulator of glucose
metabolism in prostate cancer cells18. Therefore, AR could be
responsible for the increased glucose flux observed in ARI-
resistant cells. Intracellular glucose levels remained unchanged
upon AR depletion in the different cell lines (Supplementary
Fig. 4d). In contrast, knockdown of the receptor strongly
impaired glucose utilisation in resistant cells, as illustrated by
reduced amounts of labelled isotopes of numerous glycolytic
intermediates (Fig. 4a). Overall, this effect was much less
pronounced in wild type LNCaP cells. In addition, AR-depleted
cells displayed reduced expression of ACC and ACLY (Fig. 4b),
reinforcing the idea that AR is reprogrammed to promote fatty
acid synthesis from glucose in resistant cells.
Proteomic signature associated with resistance to ARI. Due to
the major metabolic reprogramming observed in ARI-resistant
cells, we hypothesised that some initially dispensable enzymes
could become essential in maintaining the resistant phenotype.
Such candidates would represent interesting targets/biomarkers
of ARI resistance. Therefore, we used our proteomic dataset to
identify proteins that were consistently modulated in all three
ARI-resistant cell lines, in both 2D and 3D conditions. We gen-
erated a proteomic panel consisting of 13 candidates that were
differentially regulated upon resistance to AR inhibition, inde-
pendent of the type of inhibitor or the culture conditions (Fig. 5a,
Table 1). Identification of well-established factors associated with
CRPC such as prostate specific antigen (PSA) or prostate specific
membrane antigen (PSMA/FOLH1) strengthened the validity of
the proteins identified. Of note, we identified several candidates,
mainly enzymes involved in redox processes, which have not yet
been reported in prostate cancer (Table 1).
Among these proteins, the mitochondrial 2,4-dienoyl-CoA
reductase DECR1 was consistently upregulated in ARI-resistant
cells when compared to WT LNCaP. DECR1 is an auxiliary
enzyme involved in the degradation of polyunsaturated fatty acid
and might therefore be important to support the rewired lipid
metabolism associated with ARI resistance (Fig. 3). We first
confirmed that DECR1 was overexpressed in ARI-resistant cells
(Fig. 5b). Interestingly, acute treatment of multiple AR-proficient
prostate cancer cell lines with any of the AR inhibitors was
sufficient to modulate DECR1 expression (Fig. 5c) and transient
silencing of DECR1 potentiated the effect of enzalutamide in C4-
2 cells, a CRPC derivative of LNCaP (Fig. 5d). Conversely,
transient overexpression of DECR1 marginally increased cell
proliferation in LNCaP cells cultured in the presence of
enzalutamide (Fig. 5e).
Potential AR-binding sites have been reported in the DECR1
gene25, therefore we sought to test the ability of AR to directly
regulate DECR1. AR silencing did not affect DECR1 protein levels
in any of the LNCaP derivatives (Supplementary Fig. 5a).
Similarly, while short-term androgen deprivation induced
DECR1 expression in LNCaP, treatment with dihydrotestoster-
one (DHT) did not show any additional effect (Supplementary
Fig. 5b). Finally, AR binding at the promoter of DECR1 was
low in both WT and ARI-resistant LNCaP and was not
Fig. 2 Omics analysis of ARI-resistant cells reveal altered glucose metabolism. a Enriched pathways upregulated in the proteomic analysis of ARI-
resistant cells when compared to WT LNCaP. Selected proteins were significantly modulated in at least 2 out of 3 conditions. Pathway enrichment analysis
was performed using the STRING database (http://string-db.org). b Steady-state levels of significantly regulated metabolites in ARI-resistant cells when
compared to WT LNCaP (FC > 1.5, p < 0.05 using a 1-way ANOVA with a Dunnett’s multiple comparisons test). Selected metabolites were significantly
modulated in at least 2 out of 3 conditions. c Isotopologue distribution of selected metabolites in ARI-resistant and WT LNCaP cells following 13C-glucose
incorporation for 1 h. d Isotopologue distribution of pyruvate and phosphoenolpyruvate in ARI-resistant and WT LNCaP cells following 13C-glucose
incorporation for 24 h. e Isotopologue distribution of reduced glutathione (GSH) in ARI-resistant and WT LNCaP cells following 13C-glucose incorporation
for 24 h. b–e Data are presented as mean values +/− SD. c–e *p-value of labelled fraction < 0.05 using a 1-way ANOVA with a Dunnett’s multiple
comparisons test. DHAP dihydroxyacetone-phosphate, PEP phosphoenolpyruvate, GSH reduced glutathione, GSSG oxidised glutathione. Source data are
provided as a Source data File.
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significantly enriched in comparison to negative control H19
(Supplementary Fig. 5c), suggesting that DECR1 might not be a
direct AR-target.
Altogether, these results suggested that DECR1 expression
might be a part of an adaptive response to AR inhibition and
prompted us to further explore the role of this protein in the
context of CRPC.
DECR1 is associated with poor prognosis in CRPC. In vivo,
DECR1 expression was strongly upregulated in AR-proficient
CRPC orthografts derived from LNCaP AI and VCaP CR cells
grown under castrated condition (ADT) (Fig. 5f). Using immu-
nohistochemistry, we further examined DECR1 protein expres-
sion on a tissue microarray (TMA) of patients that had been
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the majority of the patients (9 out of 14), DECR1 staining was
increased after recurrence (positive Δ histoscore) (Fig. 5g).
Similarly, DECR1 expression was also upregulated in tumours
persisting after castration therapy in the Nkx3.1 Ptenfl+/−
Spry2fl+/− genetically engineered mouse model, an AR-driven
model of CRPC26 (Supplementary Fig. 5d).
We next assessed the clinical relevance of DECR1 in prostate
cancer. In silico analysis of the cancer genome atlas (TCGA)
dataset revealed that DECR1 expression was frequently dysregu-
lated in prostate cancer, at both gene and transcript levels
(Fig. 5h). DECR1 mRNA expression level was significantly higher
in prostate tumour samples than in normal adjacent tissues, and
high DECR1 expression was associated with significantly reduced
patient disease-free survival (Fig. 5i, j). In another dataset27, high
DECR1 expression was observed in more than 70% of metastases
collected from CRPC patients, independent of the site of
metastasis (Supplementary Fig. 5e). Analysis of a third indepen-
dent cohort28 further confirmed that DECR1 expression was
highest in metastatic tumours (Supplementary Fig. 5f) and
strongly correlated with worse outcome in metastatic patients
(Supplementary Fig. 5g).
DECR1 maintains lipid homeostasis in CRPC cells. To evaluate
the functional impact of DECR1 in CRPC, we used the isogenic
pair of LNCaP (androgen-responsive) and LNCaP-AI (androgen-
independent) cell lines. LNCaP AI cells displayed higher levels of
both the DECR1 protein and mRNA than parental LNCaP
(Fig. 6a, Supplementary Fig. 6a).
Using CRISPR-CAS9 gene editing technology, we deleted the
DECR1 gene in LNCaP-AI cells, referred to as DECR1 KO cells
thereafter (Supplementary Fig. 6b). Loss of DECR1 expression
impaired in vitro cellular proliferation of LNCaP-AI cells by an
average of 32% (Fig. 6b). To evaluate the impact of DECR1
deletion on cell metabolism, we performed metabolomic profiling
of small polar metabolites in DECR1 KO and CTL cells
(Supplementary Fig. 6c). We did not observe any significant
changes in the expression of TCA cycle metabolites or in the
several carnitine derivatives that were identified (Supplementary
Fig. 6d), which might indicate that loss of DECR1 does not
strongly affect global β-oxidation or mitochondrial metabolism.
Interestingly, levels of dihydroxyacetone-phosphate (DHAP) and
glyceraldehyde-3-phosphate (G3P), two glycolytic intermediates,
were lower in DECR1-deficient cells compared to CTL cells. In
contrast, DECR1 KO accumulated larger amounts of glutamine
(3.5-fold), which might be reflective of their lower proliferation
rate, and phospho-ethanolamine (2-fold), an important precursor
for the synthesis of phosphatidyl-ethanolamine (PE) and
membrane lipids (Supplementary Fig. 6c). Intrigued by this
result, we decided to compare the lipid profile of DECR1 KO cells
with the one of CTL cells (Fig. 6c). In line with impaired PE
biosynthesis, lipidomic analysis revealed decreased levels of
several classes of PE in DECR1 KO cells. In addition, clustered
analysis of the differentially altered lipids highlighted an
imbalance between unsaturated and saturated lipids, with the
DECR1 KO cells accumulating elevated levels of highly
unsaturated lipids (saturation level >2) but low levels of saturated
and mono-unsaturated or bi-unsaturated molecules (saturation
level ≤ 2) (Fig. 6c). This result is exemplified by the dual
distribution of altered phosphatidylcholines (PC) molecules in
Supplementary Fig. 6e. DECR1-deficient cells also displayed high
levels of ceramides (Fig. 6d), which have been shown to perturb
cellular homeostasis and to be detrimental to mitochondrial
function29. To better understand how DECR1 influences fatty
acid (FA) metabolism and changes in FA saturation, we further
performed GC-MS analyses to measure the FA composition of
CTL and DECR1 KO cells. In comparison with CTL cells, DECR1
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KO cells presented higher levels of polyunsaturated fatty acids
(PUFAs), especially arachidonic acid (AA) and docosahexaenoic
acid (DHA), while they showed decreased levels of the
monounsaturated fatty acids (MUFAs) palmitoleic acid (PalA)
and sapienate (SA) (Fig. 6e). While MUFAs have been shown to
protect against oxidative stress30, cellular accumulation of PUFAs
can result in lipid peroxidation and induction of ferroptosis31.
PUFA-induced toxicity mainly results from accumulation of free
PUFAs. Therefore, we also compared the intracellular pool of free
FA between the different conditions. Similar to the analysis of
total FA, we found that DECR1 KO cells exhibited increased
levels of free PUFAs (DHA and AA, although the latter only
reached significance for one of the KO clones) and decreased
levels of free MUFAs (PalA and SA) (Fig. 6f). This change in FA
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composition was not associated with differences in FA synthesis
(Supplementary Fig. 6f). Finally, DECR1-deficient cells were less
sensitive than CTL to the addition of palmitate, a saturated fatty
acid (Supplementary Fig. 6h), and palmitate treatment was able to
abolish DECR1-dependent decrease in cell proliferation (Supple-
mentary Fig. 6i).
Loss of DECR1 sensitises CRPC cells to ferroptosis. Increased
polyunsaturated lipid content can also increase susceptibility to
lipid peroxidation and trigger ferroptosis. In line with this idea,
loss of DECR1 resulted in increased expression of the ER cha-
perones BIP and DNAJC3, and lead to an activation of the
unfolded protein response, a process known to be associated with
impaired lipid homeostasis, as evidenced by strong upregulations
of CHOP and the spliced isoform of XBP1 (Fig. 6g). DECR1 KO
cells also displayed elevated levels of the lipid-detoxifying enzyme
glutathione peroxidase 4 (GPX4)32 (Fig. 6h). Therefore, we
treated CTL and DECR1 KO cells with RSL3, a specific GPX4
inhibitor, to induce ferroptosis. DECR1 KO cells displayed
increased sensitivity to GPX4 inhibition (Fig. 6i, Supplementary
Fig. 6g). Co-treatment with either Trolox or liproxstatin, two
inhibitors of ferroptosis, was able to rescue cell proliferation and
restore cell morphology of DECR1 KO cells under RSL3 treat-
ment (Fig. 6j, Supplementary Fig. 6g). Taken together, these
results suggest a role for DECR1 in regulating redox homeostasis
in a lipid-dependent manner.
DECR1 expression is required for in vivo CRPC tumour
growth. In contrast to LNCaP, LNCaP-AI cells are able to form
solid tumours when injected orthotopically into the prostate of
castrated mice. Therefore, we examined the impact of reduced
DECR1 expression on the growth of CRPC tumours in vivo.
Silencing of DECR1 impaired tumour growth in castrated mice,
significantly reducing tumour volume by an average of 41%
(assessed by ultrasonography; Fig. 7a). Furthermore, DECR1 KO
tumours were highly necrotic and displayed a lower level of cel-
lularity than the control tumours (Fig. 7b).
Raman spectroscopy was performed on the tumour slides to
test if loss of DECR1 expression perturbed intra-tumoural
contents of lipids and cholesterol-based compounds. Raman
spectroscopy is a non-destructive label-free analytical technique
that can provide rich molecularly specific information without
isolation of the specific molecules under investigation. Mixtures
of molecules can be identified from their specific vibrations, with
lipids in particular having a high Raman cross section making
them ideal candidates for study by this technique. Lipid-
associated molecules were represented by a band at 2845 cm−1,
while cholesterol content was demonstrated by a band around
2880 cm−133. Raman spectra obtained for DECR1 KO tumours
demonstrated reduced intensity of bands at 2845 cm−1 (lipids)
and 2880 cm−1 (cholesterol), suggesting that DECR1-deficient
tumours had reduced levels of lipid and cholesterol compounds
in comparison to control tumours (Fig. 7c). Finally, LC-MS
Fig. 5 DECR1 is a potential target for CRPC. a Venn diagrams highlighting proteins commonly modulated (p-value < 0.05, FC > 1.5) in ARI-resistant cells
cultured in 2D and 3D conditions. Upregulated proteins are on top; downregulated proteins are into brackets. bWestern blot analysis of DECR1 expression
in WT and ARI-resistant LNCaP cells. c Western blot analysis of DECR1 expression in AR+ prostate cancer cells following acute AR inhibition for 48 h.
d Cell proliferation of C4-2 cells silenced for DECR1 expression and treated with enzalutamide (20 µM—48 h). Cell count is normalised to untreated control
(siCTL). e Cell proliferation of LNCaP cells overexpressing DECR1 and treated with enzalutamide (20 µM—48 h). Cell count is normalised to untreated
empty vector (EV OE). f Western blot analysis of DECR1 expression in hormone naïve (LNCaP, VCaP) and castration-resistant (LNCaP AI, VCaP CR)
tumour orthografts. g Immunohistochemical staining (left) and quantification (right) of DECR1 expression in CRPC tissue samples. Data are represented as
difference in histoscore between post-treatment and pre-treatment biopsies. Scale bar represents 100 µm. h Percentage of prostate cancer patients
showing genomic (copy number gain or amplification) or mRNA alteration (z-score= 1.5) for DECR1 using the TCGA dataset. i Gene expression analysis of
DECR1 in normal and tumoural prostate tissues according to the TCGA dataset (n= 498). Centre line corresponds to median of data, top and bottom of
box correspond to 75th and 25th percentile, respectively. Whiskers extend to adjacent values (minimum and maximum data points not considered
outliers). j Kaplan–Meier survival analysis of prostate cancer patients stratified according to DECR1 expression using the TCGA dataset. b, c, f HSC70 is
used as a sample loading control. d, e Data are presented as mean values +/− SD. d, e *p-value < 0.05 using a 1-way ANOVA with a Dunnett’s multiple
comparisons test. g statistical analysis was performed using a Wilcoxon matched-pair signed-rank test (n= 14). i statistical analysis was performed using a
pairwise ANOVA. j statistical analysis was performed using a logrank test. Source data are provided as a Source data File.
Table 1 Proteins commonly modulated in ARI (FC= 1.5, p < 0.05) in 2D and 3D cultures.
2D Comparison (log2(FC)) 3D Comparison (log2(FC))
Gene name Protein name Bicalut./WT Apalut./WT Enzalut./WT Bicalut./WT Apalut./WT Enzalut./WT
SQRDL Sulphide:quinone oxidoreductase,
mitochondrial
4.10 5.01 4.87 2.12 3.14 3.30
EPHX1 Epoxide hydrolase 1 1.31 1.81 2.55 0.78 2.29 2.62
ATP1B1 Sodium/potassium-transporting ATPase
subunit beta-1
0.96 2.22 2.40 1.17 1.77 1.26
ALDH3A2 Fatty aldehyde dehydrogenase 2.41 1.47 2.05 0.74 0.93 1.33
DECR1 2,4-dienoyl-CoA reductase, mitochondrial 1.08 1.73 1.28 1.23 1.76 1.09
TST Thiosulfate sulfurtransferase 1.33 1.00 1.85 0.99 0.80 0.95
FOLH1 Glutamate carboxypeptidase 2 0.59 1.04 1.17 0.61 1.41 0.87
USP5 Ubiquitin carboxyl-terminal hydrolase 5 0.87 0.81 1.37 0.81 0.85 0.66
NASP Nuclear autoantigenic sperm protein −1.05 −1.41 −1.34 −0.72 −0.99 −0.75
VTA1 Vacuolar protein sorting-associated protein
VTA1 homologue
−1.24 −1.30 −1.42 −0.88 −0.82 −1.34
TPT1 Translationally-controlled tumour protein −1.35 −1.81 −2.26 −1.29 −1.15 −2.40
PDLIM5 PDZ and LIM domain protein 5 −2.66 −2.27 −2.98 −2.71 −3.00 −3.36
KLK3 Prostate-specific antigen −2.63 −2.83 −2.45 −4.39 −3.79 −3.61
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lipidomics performed on frozen tumours confirmed data from the
Raman spectroscopy. DECR1 KO tumours presented a pro-
nounced decrease in several highly abundant triglycerides species,
which accounted for a large proportion of total lipid content
(Fig. 7d). Moreover, similar to what is observed in vitro, DECR1
KO tumours showed an increase in several ceramides and
multiple polyunsaturated phospholipids (Fig. 7d).
Discussion
Despite being the main target of hormonal therapies for over five
decades, AR remains the key driver of prostate cancer progression
to CRPC. The recent clinical success of selective ARI in
improving CRPC patient survival has further reinforced the
importance of androgen receptor as a target for therapy. How-
ever, long-term resistance to AR-targeted therapies inevitably
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leads to tumour relapse, and therefore a better understanding of
the molecular mechanisms underlying therapy resistance repre-
sents an urgent clinical need and a top research priority.
Cancer cells have developed multiple ways to escape AR-
directed targeting. While situations of AR loss34 or bypass17 have
been reported, strong evidences suggest that AR signalling
remains active in the majority of CRPC patients35. Along with the
acquisition of point mutations12–14, AR gene amplification as well
as overexpression at mRNA and protein level36 has been sug-
gested to support enzalutamide resistance by activating AR-
dependent and independent pathways37,38. In line with these
reports, we found that AR signalling remained highly active in
cells resistant to bicalutamide, apalutamide and enzalutamide. AR
transcriptional reprogramming was evidenced by AR nuclear
localisation, and varying levels of expression for canonical AR
targets (namely KLK3 and FKBP5).
ARI-resistant cells had their metabolism altered towards
increased glucose consumption. In support of our findings,
increased glucose metabolism has been associated with late stage
CRPC20, and inhibition of glycolysis synergised with enzaluta-
mide treatment39. We initially thought that a potential driver for
this metabolic rearrangement could be the master metabolic
sensor AMPK, which has been proposed as a target in the context
of enzalutamide resistance24,40. However, while ARI-resistant
cells indeed showed increased AMPK expression, silencing of this
protein only moderately affected glucose utilisation. In contrast,
AR silencing dramatically reduced the glucose flux in the resistant
cells, suggesting that this metabolic reprogramming depends on
AR itself. AR is an important regulator of cell metabolism in the
prostate18. In an elegant study, Massie and colleagues demon-
strated that AR could directly regulate aerobic glycolysis and
glucose-derived anabolism under conditions of androgen stimu-
lation by activating the transcription of key biosynthetic enzymes
such as HK1, HK2, ACC, and FASN. Interestingly, tracing of 13C-
glucose incorporation into fatty acids revealed that the higher rate
of glucose oxidation observed in ARI-resistant cells contributes to
enhanced de novo fatty acid synthesis. In addition to reducing the
glucose flux, AR silencing in these cells also led to a selective
downregulation of the lipogenic enzymes ACLY and ACC. Thus,
the metabolic phenotype observed in ARI-resistant LNCaP cells is
highly reminiscent of the one observed in DHT-activated
LNCaP18, and therefore represents a metabolic vulnerability of
therapeutic potential. In line with this idea, pharmacological
inhibition of the mitochondrial pyruvate carrier has recently been
demonstrated to specifically impair AR-driven tumour growth41.
In addition to glucose metabolism, our proteomic analysis
revealed that many mitochondrial proteins were overexpressed in
the resistant cells. The metabolic rewiring observed in ARI-
resistant cells ultimately led to an important reorganisation of the
lipidome of these cells, characterised by a strong accumulation of
polyunsaturated triglycerides and sphingolipids. Therefore, while
the influence of mitochondria on ARI resistance remains to be
fully tested, we can hypothesise that increased mitochondrial
metabolism in the resistant cells was needed to support FA and
lipid synthesis, via the generation of citrate and acetyl-CoA, and
also to regulate lipid homeostasis, for example through an
increase in β-oxidation. This hypothesis is further supported by
the high expression of several transcription factors involved in
mitochondrial metabolism and lipid homeostasis, such as PGC1α,
PPARγ and LXR, in ARI-resistant cells. Both lipid synthesis and
fatty acid degradation are highly dysregulated processes in
prostate cancer20, and these pathways have been the subject of
intense drug development42,43. On one hand, targeting enzymes
involved in de novo lipid synthesis, such as ACLY44 or FASN, is
an active research focus with Phase 2 clinical trials currently
opened42. On the other hand, fatty acid oxidation (FAO) can
promote cancer cell survival under stress conditions45,46 and
pharmacological inhibition of that pathway proved effective in
multiple cancers47,48. In prostate, increased beta-oxidation has
been shown to promote prostate cancer cell survival49 while
inhibition of lipid catabolism, achieved via pharmacological
inhibition or CPT1a silencing, decreased tumour growth and
restored enzalutamide sensitivity50,51.
Lastly, our proteomic analysis highlighted DECR1, an auxiliary
enzyme of β-oxidation, as a protein robustly associated with ARI
resistance. In addition, ARI-resistant cell lines were characterised
by high levels of multiple metabolic enzymes involved in lipid
metabolism (DECR2, ACSL1, HIBCH, HIBADH, etc.). Therefore,
we speculated that DECR1 was overexpressed upon resistance to
AR inhibition as part of an adaptive response that allows resistant
cells to cope with their rewired lipid metabolism. High DECR1
expression has previously been detected in proteomic analyses
comparing localised prostate tumours to non-malignant lesions52
or in metastatic specimens compared to localised tumours53. In
addition to that, we demonstrated that high expression of DECR1
in primary and metastatic prostate cancer correlates with unfa-
vourable patient survival outcomes. Short term ARI treatment or
androgen withdrawal induced DECR1 expression in prostate cell
lines, while long-term ADT treatment in patients and tumour-
bearing mice resulted in strong upregulation of the protein.
However, DECR1 levels in prostate cells were not affected by AR
silencing or DHT treatment, suggesting that DECR1 might be
part of a long-term, rather than acute, response to AR inhibition.
Future studies will be needed to understand the mechanisms
involved in the regulation of DECR1 during CRPC development.
DECR1 is a mitochondrial enzyme involved in the auxiliary
pathway of beta-oxidation and critically regulates PUFAs in
entering the degradation cycle within the mitochondria. To date,
Fig. 6 DECR1 loss alters lipid homeostasis and sensitises CRPC cells to ferroptosis. aWestern blot analysis of DECR1 expression in LNCaP and LNCaP AI
cells. b Cell proliferation of DECR1 KO (knockout) and untargeted control (CTL) cells after 72 h. Cell count is normalised to initial number of cells at the
start of the experiment. c Hierarchical clustering of significantly altered lipids in DECR1 KO cells when compared to CTL cells (FC > 1.2). Selected lipids
were significantly altered in at least one of the two KO cells (p < 0.05 using two-sided Student’s t-test). Values are expressed as log(FC). d Steady-state
levels of significantly altered ceramides (Cer) in DECR1 KO cells when compared to CTL cells (FC > 1.2). Selected lipids were significantly altered in at least
one of the two KO cells (p < 0.05 using two-sided Student’s t-test). e Absolute concentration of total MUFAs (left panel) and total PUFAs (right panel) in
CTL and DECR1 KO cells, quantified by GC-MS. f Absolute concentration of free MUFAs (left panel) and free PUFAs (right panel) in CTL and DECR1 KO
cells, quantified by GC-MS. g Western blot analysis of BIP, DNAJC3, XBP1s and CHOP expression in DECR1 KO and CTL cells. h Western blot analysis of
GPX4 expression in DECR1 KO and CTL cells. i Cell proliferation of DECR1 KO and CTL cells treated for 48 hours with RSL3 (10 µM). Cell count is
normalised to initial number of cells. j Cell proliferation of DECR1 KO and CTL cells treated for 48 h with RSL3 (10 µM) and Trolox (20 µM) or Liproxstatin
(50 nM). Cell count is normalised to initial number of cells. a, g, h HSC70 is used as a sample loading control. b, d, e, f, i, j Data are presented as mean
values +/− SD. b, e, f, i, j *p-value < 0.05 using a 1-way ANOVA with a Dunnett’s multiple comparisons test. DG: diacylglycerol, PC phosphatidylcholine,
PE phosphatidylethanolamine, PG phosphatidylglycerol, PI phosphatidylinositol, PS phosphatidylserine, SM sphingomyelin, TG triglyceride. Source data are
provided as a Source data File.
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the role of DECR1 in cancer has not been well-studied. In con-
trast to our data, DECR1 was proposed to act as a tumour sup-
pressor in HER2-positive breast cancer54. However, in the same
study, DECR1 overexpression was also shown to protect cancer
cells from glucose withdrawal-induced apoptosis. Interestingly,
Decr1−/− mice develop hypoglycaemia under metabolic stress
conditions55, suggesting a link between DECR1 and glucose
metabolism. We also observed decreased levels of the glycolytic
intermediates DHAP and G3P in DECR1-deficient cells (Sup-
plementary Fig. 6c). However, the main phenotype described in
Decr1−/− mice was the disturbance of fatty acid balance, with
Decr1−/− mice showing accumulation of unsaturated fatty acids
in the form of liver triacylglycerols55. Therefore, in the context of
CRPC, an appealing hypothesis would be that DECR1-mediated
lipid rearrangement is necessary to support the rewired meta-
bolism of ARI-resistant cells, and its associated stress stimuli
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(e.g., redox stress). Similarly to what is observed in Decr1−/−
mice, we were able to demonstrate that DECR1 was critically
required for lipid homeostasis in CRPC. Indeed, DECR1 KO cells
accumulated high levels of polyunsaturated lipids and low levels
of saturated lipids compared to control cells. This observation was
further supported by an accumulation of total and free PUFAs
together with a decrease in several MUFAs, such as the recently-
reported MUFA sapienate56, in DECR1-deficient cells. Interest-
ingly, we did not observe any change in the levels of the highly
abundant MUFA oleic acid (18:1). Because DECR1 acts primarily
on PUFAs; this result suggests that changes in PUFA composi-
tion, rather than MUFA, might contribute to a greater extent to
the generation of the DECR1 KO phenotype. This imbalance in
turn resulted in an activation of the ER stress response pathway
and an increased susceptibility to lipid peroxidation, evidenced by
the observed increased sensitivity to GPX4 inhibition. Accumu-
lation of PUFAs increases the risk of lipid peroxidation and cell
death31, and pharmacological inhibition of GPX4, an important
lipid-detoxifying enzyme, has recently been proposed as a pro-
mising therapeutic strategy in drug-resistant tumours32. More-
over, specific PUFA-derived mediators, such as specialised pro-
resolving mediators, have recently attracted interest due to their
anti-tumoural properties57. Therefore, by regulating lipid
saturation level, DECR1 might act in several ways to support
cancer cell survival. Finally, changes in membrane-lipid satura-
tion are known to cause ER stress58,59 and, interestingly, DECR1
has been reported to be a strong interacting partner of DNaK, the
homologue of the Hsp70 chaperone in bacteria60. Taken together,
these results suggest that DECR1 may contribute to increase
metabolic flexibility of cancer cells under stress conditions, and
uncover an unexpected link between DECR1 function and ER
homeostasis.
In conclusion, our data suggest that, despite differences in
available AR-targeted therapies, castration-resistant prostate
cancer cells develop a shared metabolic phenotype in response to
AR inhibition. In addition to being directly targetable, these
metabolic adaptations are associated with the emergence of a
specific set of proteins, such as DECR1, which could serve as
clinically relevant biomarkers and/or therapeutic targets. These
findings support the idea of targeting specific metabolic pathways
in combination with AR inhibition, and open doors for the
development of future therapies.
Methods
2D and 3D cell culture. All cells were cultured in RPMI (Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) medium supplemented with 10% foetal bovine
serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM
glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), and maintained
at 37 °C under 5% CO2. LNCaP (ATCC CRL-1740) and C4-2 cells (ATCC
CRL3314) were obtained from ATCC. CWR22Res cells (hormone-responsive
variant of CWR22 cells) were obtained from Case Western Reserve University,
Cleveland, Ohio. The bicalutamide-resistant and enzalutamide-resistant LNCaP
derivatives (LNCaP Bicalut. Res. and LNCaP Enzalut. Res.) were generated by
chronic treatment of LNCaP cells with respective 10 µM bicalutamide (Sigma
Aldrich, St Louis, MI, USA) or 10 µM enzalutamide (Selleckchem, Munich, Ger-
many) for 4 months until non-clonal surviving populations of cells were propa-
gated. For the apalutamide-resistant LNCaP cell line (LNCaP Apalut. Res.), cells
were grown as above in 10 µM apalutamide (ARN509, Selleckchem, Munich,
Germany) and a clonal population of surviving cells were expanded. All LNCaP
derivatives were grown routinely in 10 µM of their respective anti-androgen.
LNCaP-AI cells were maintained in phenol-free RPMI (Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10% charcoal-stripped serum
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM glutamine.
For 3D culture, cells were suspended in 100% Matrigel (Corning, NY, USA) and
seeded in 6-wells plate. Matrigel was allowed to solidify for 15 min at 37 °C before
being entirely covered with 3 ml of culture medium. Cells were allowed to grow for
five passages before each experiment. For each passage, Matrigel was mechanically
disrupted and organoids were gently centrifuged at 300×g for 5 min. The organoid
pellet was washed twice with PBS, and ¼ was finally resuspended in 100% Matrigel.
Proteomic analysis. 6–8 × 105 cells were seeded in 6-well plates and allowed to
attach overnight. The next day, culture medium was replaced with fresh RPMI and
cells were allowed to grow for another 48 h. Cells were then washed with PBS and
lysed in 8 M Urea. Reduced proteins were alkylated using 55 mM Iodoacetamide
for 1 h at room temperature. Alkylated proteins were then submitted to a two-step
digestion at 35 °C with endoproteinase Lys-C (Alpha Laboratories, Eastleigh, UK)
for 1 h, followed by trypsin (Promega, Madison, WI, USA) digestion overnight.
Digested peptides were desalted using StageTip61 and separated by nanoscale
C18 reverse-phase liquid chromatography performed on an EASY-nLC II (Thermo
Fisher Scientific, Waltham, MA, USA) coupled to an Orbitrap Velos mass spectro-
meter (Thermo Fisher Scientific, Waltham, MA, USA). Elution was carried out
using a binary gradient with water (buffer A) and 80% acetonitrile (buffer B), both
containing 0.1% of formic acid. Peptide mixtures were separated at 200 nl min−1
flow, using a 20 cm fused silica emitter (New Objective) packed in-house with
ReproSil-Pur C18-AQ, 1.9 μm resin (Dr. Maisch GmbH). Packed emitter was kept
at 35 °C by means of a column oven integrated into the nanoelectrospray ion
source (Sonation, Biberach, Germany). The gradient used started at 2% of buffer B,
kept at same percentage for 5 min, then increased to 30% over 90 min and then
to 60% over 15 min. Finally, a column wash was performed ramping to 80% of B in
5 min and then to 95% of B in 1 min followed by a 13 min re-equilibration at 2% B
for a total duration of 129 min. The eluting peptide solutions were automatically
(online) electrosprayed into the mass spectrometer via a nanoelectrospray ion
source (Thermo Fisher Scientific, Waltham, MA, USA). An Active Background Ion
Reduction Device (ABIRD, ESI Source Solutions, Woburn, MA, USA) was used to
decrease ambient contaminant signal level.
Samples were acquired on a Linear Trap Quadrupole—Orbitrap Velos Mass
spectrometer using a spray voltage, 2.4 kV, and an ion transfer tube temperature of
200 °C. The mass spectrometer was operated in positive ion mode and used in
data-dependent acquisition mode (DDA). A full scan (FT-MS) was acquired at a
target value of 1,000,000 ions with resolution R= 60,000 over mass range of
350–1600 amu. The top ten most intense ions were selected for fragmentation in
the linear ion trap using collision induced dissociation (CID) using a maximum
injection time of 25 ms or a target value of 5000 ions. Multiply charged ions from
two to five charges having intensity greater than 5000 counts were selected through
a 2 amu window and fragmented using normalised collision energy of 36 for 10 ms.
Former target ions selected for MS/MS were dynamically excluded for 25 s.
The MS Raw files were processed with MaxQuant software62 version 1.5.5.1 and
searched with Andromeda search engine63, querying UniProt64 Homo sapiens (09/
07/2016; 92,939 entries). The database was searched requiring specificity for trypsin
cleavage and allowing maximum two missed cleavages. Methionine oxidation and
N-terminal acetylation were specified as variable modifications, and cysteine
carbamidomethylation as fixed modification. The peptide, protein and site false
discovery rate (FDR) was set to 1%. Proteins were quantified according to the label-
free quantification algorithm available in MaxQuant65. MaxQuant output was
further processed and analysed using Perseus software version 1.5.5.366. The
common reverse and contaminant hits (as defined in MaxQuant output) were
Fig. 7 DECR1 KO affects lipid metabolism and decreases CRPC tumour growth. a Representative pictures of LNCaP AI CTL (top image) or DECR1 KO
(bottom image) tumour orthografts monitored by ultrasound imaging (left). Quantification of tumour volume using ultrasonography (right). b
Representative pictures of hematoxylin/eosin staining on orthografts from LNCaP AI CTL (top) or DECR1 KO (bottom) cells. C= cancer cells, N= necrotic
region. Quantification of the proportion of cancer cells (right). Scale bar represents 1000 µm. c Representative heatmaps on data from Raman spectroscopy
using 532 nm excitation (intensity at frequency 2845 cm-1/intensity at frequency 2935 cm-1) on LNCaP AI CTL (top) and DECR1 KO (bottom) derived
orthografts (left). Average Raman spectra of LNCaP AI CTL (grey) or DECR1 KO (magenta) orthografts (middle) and quantification of tumour lipid content
using the 2845 cm−1-peak (right panel). AU= arbitrary unit. d Heatmap illustrating the steady-state levels of significantly regulated lipids in DECR1-
deficient tumours when compared to CTL tumours (FC > 1.5, p < 0.05 using a two-tailed Student’s t-test). Values are expressed as z-score. a–c Data are
presented as mean values +/− SD. a–c *p-value < 0.05 using a two-tailed Mann–Whitney U-test. BMP Bis(monoacylglycero)phosphate, Cer ceramide, PC
phosphatidylcholine, PE phosphatidylethanolamine, PG phosphatidylglycerol, PI phosphatidylinositol, PS phosphatidylserine, TG triglyceride. Source data
are provided as a Source data File.
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removed. Only protein groups identified with at least one uniquely assigned
peptide were used for the analysis. Significantly enriched proteins were selected
using a two-sided t-test analysis with a 5% FDR.
Metabolomic analysis. 6–8 × 105 cells were seeded in 6-well plates and allowed to
attach overnight. The next day, culture medium was replaced with fresh RPMI
medium, and cells were allowed to grow for another 48 h. For tracing experiments,
cells were further incubated in glucose-free RPMI (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 10% FBS and 10 mM 13C-glucose (CLM-
1396, Cambridge Isotopes Laboratories, UK) prior to extraction. Cells were then
washed twice with ice-cold PBS and polar metabolites were extracted in a MetOH-
Acetonitrile-H2O (50-30-20) buffer for 5 min under gentle agitation. Collected
supernatant was vigorously mixed for 10 min and centrifuged at 16,100×g for ten
additional minutes. All the steps were performed at 4 °C. Finally, supernatant was
transferred to glass HPLC vials (Thermo Fisher Scientific, Waltham, MA, USA)
and analysed using HPLC-MS.
Samples were analysed according to the refs. 67,68. A Q Exactive Orbitrap mass
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) was used together
with a Thermo Ultimate 3000 HPLC system. The HPLC setup consisted of a ZIC-
pHILIC column (SeQuant, 150 × 2.1 mm, 5 µm, Merck KGaA, Darmstadt,
Germany), with a ZIC-pHILIC guard column (SeQuant, 20 × 2.1 mm) and an
initial mobile phase of 20% 20 mM ammonium carbonate, pH 9.2, and 80%
acetonitrile. Cell and media extracts (5 µl) were injected and metabolites were
separated over a 15 min mobile phase gradient, decreasing the acetonitrile content
to 20%, at a flow rate of 200 μl min−1 and a column temperature of 45 °C. The total
analysis time was 25 min. All metabolites were detected across a mass range of
75–1000m/z using the Q Exactive mass spectrometer at a resolution of 35,000 (at
200m/z), with electrospray ionisation (ESI) and polarity switching to enable both
positive and negative ions to be determined in the same run. Lock masses were
used and the mass accuracy obtained for all metabolites was below 5 ppm. Data
were acquired with Thermo Xcalibur software.
The peak areas of different metabolites were determined using Thermo
TraceFinder 4.0 software, where metabolites were identified by the exact mass of
the singly charged ion and by known retention time on the HPLC column.
Commercial standards of all metabolites detected had been analysed previously on
this LC-MS system with the pHILIC column. The 13C labelling patterns were
determined by measuring peak areas for the accurate mass of each isotopologue of
many metabolites. Intracellular metabolites were normalised to protein content of
the cells, measured at the end of the experiment by the BCA assay (Thermo Fisher
Scientific, Waltham, MA, USA).
Lipidomic analysis. Lipids were extracted from cells with 0.8 ml 1:1
butanol–methanol after media removal. Before extraction, an internal standard
(Splash Lipidomix, Avanti Polar Lipids, Alabaster, AL, USA) was added to the
extraction buffer and further used as a quality control. Lipids were separated on an
Acquity UPLC CSH C18 column (100 × 2.1 mm; 1.7 µm) (Waters corporation,
Milford, MA, USA) maintained at 60 °C. The mobile phases consisted of 60:40
ACN:H2O with 10 mM ammonium formate, 0.1% formic acid and 5 µM of
phosphoric acid (A) and 90:10 IPA:ACN with 10 mM ammonium formate, 0.1%
formic acid and 5 µM phosphoric acid (B). The gradient was as follows: 0–2 min
30% (B); 2–8 min 50% (B); 8–15 min 99% (B), 15–16 min 99% (B), 16–17 min 30%
(B). Sample temperature was maintained at 6 °C in the autosampler and 2 µl of
sample were injected.
Analysis of polar and non-polar lipids were conducted using an LC-MS system
including an Ultimate 3000 HPLC (Thermo Fisher Scientific, Waltham, MA, USA)
coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific,
Waltham, MA, USA). Q-Exactive Orbitrap MS instrument was operated in both
positive and negative polarities, using the following parameters: mass range
240–1200m/z (positive) and 240–1600 (negative), spray voltage 3.8 kV (ESI+) and
3 kV (ESI−), sheath gas (nitrogen) flow rate 60 units, auxiliary gas (nitrogen) flow
rate 25 units, capillary temperature (320 °C), full scan MS1 mass resolving power
70,000. Data dependent fragmentation (dd-MS/MS) parameters for each polarity as
follows: TopN: 10, resolution 17,500 units, maximum injection time: 25 ms,
automatic gain control target: 5e5 and normalised collision energy of 20 and 25
(arbitrary units) in positive polarity. TopN: 5, resolution 17,500 units, maximum
injection time: 80 ms automatic gain control target: 5e5 and normalised collision
energy of 20 and 30 (arbitrary units) in negative polarity. The instrument was
externally calibrated to <1 ppm using ESI positive and negative calibration
solutions (Thermo Fisher Scientific, Waltham, MA, USA). Peak detection and
integration from Raw data were processed using Compound Discoverer 3.0
(Thermo Fisher Scientific, Waltham, MA, USA). Files were also converted to mgf
format using MSConvert software and MS2 files were searched against LipidBlast
database using LipiDex software69–71. Peak intensities were normalised to cell
number. Heatmaps were generated in R (v.3.6.1, https://www.R-project.org) using
pHeatmap package (v.1.0.12, https://CRAN.R-project.org/package=pheatmap).
Total and free fatty acid extraction and GC-MS. Metabolite quenching and
extraction were performed according to the ref. 72–74. Every step was performed in
a mixture of dry and wet ice. Briefly, cell plates previously quenched in liquid
nitrogen were extracted with 800 µl of cold 62.5% methanol. For the measurement
of free fatty acids, two wells per sample were pooled. Cells were scraped with a
pipet tip and transferred to Eppendorf tubes. Thus, 500 µl of cold chloroform
containing 10 µg ml−1 of C17 internal standard was added and samples were
vortexed at 4 °C for 10 min. Phase separation was achieved by centrifugation at 4 °
C for 10 min, after which the chloroform phase (lower phase containing fatty
acids), the polar metabolite phase and the protein layout were separated and dried
overnight with a vacuum concentrator at 4 °C. Standard curves at a final con-
centration of 2 µM to 800 µM were also extracted for the quantification of free and
total fatty acids.
Total fatty acid samples and standards were esterified with 500 µl 2% sulfuric
acid in methanol overnight at 50 °C, while free fatty acid samples and standards
were esterified for 15 min at room temperature. Free and total fatty acids were then
extracted by addition of 600 µl hexane and 100 µl saturated NaCl. Samples were
centrifuged for 5 min and the hexane phase was separated and dried with a vacuum
concentrator Samples and standards were resuspended in 50 µl of hexane.
Fatty acids were separated with gas chromatography (8860 GC system, Agilent
Technologies, CA, USA) combined with mass spectrometry (5977B Inert MS
system, Agilent Technologies, CA, USA). One microliter of each sample was
injected (splitless mode) with an inlet temperature of 270 °C onto a DB-
FASTFAME column (30 m × 0.250 mm). Helium was used as a carrier gas with a
flow rate of 1 ml min−1. For the separation of fatty acids, the initial gradient
temperature was set at 50 °C for 1 min and increased at the ramping rate of 12 °C
min−1 to 180 °C, following by a ramping rate of 1 °C min−1 to reach 200 °C.
Finally, the final gradient temperature was set at 230 °C with a ramping rate of 5 °C
min−1 for 2 min. The temperatures of the quadrupole and the source were set at
150 °C and 230 °C, respectively. The MS system was operated under electron
impact ionisation at 70 eV and a mass range of 100–600 amu was scanned. After
the acquisition by GC-MS, an inhouse Matlab M-file was used to extract mass
distribution vectors, to integrate raw ion chromatograms and to correct by
isotopologue distributions by the natural abundance75. For the quantification of
free and total fatty acids, the total ion counts were normalised to the internal
standard (C17) and protein contents for cell extracts.
Determination of 13C fatty acids and GC-MS. 6–8 × 105 were seeded in 6-well
plates and allowed to attach overnight. The next day, culture medium was replaced
and cells were incubated in glucose-free RPMI (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 10% FBS, 2 mM glutamine and 10 mM
13C-glucose (CLM-1396, Cambridge Isotopes Laboratories, UK) for another 72 h
prior to extraction. Cells were then washed three times with ice-cold PBS and fatty
acids were extracted in a Methanol-Chloroform-PBS buffer (750 µl 1:1 v/v PBS:
methanol and 500 µl chloroform). For all samples, 50 µl of 1 mgml−1 methanolic
butylated hydroxytoluene (BHT, Sigma Aldrich, St Louis, MI, USA) and 20 µl of
0.05 mgml−1 17:0 PC (Avanti Polar Lipids, Albaster, AL, USA) as an internal
standard, were added. Samples were centrifuged at 10,000×g for 5 min before the
lower chloroform layer was extracted and dried under N2. Samples were recon-
stituted in 90 µl chloroform and incubated with 10 µl MethPrepII (Thermo Fisher
Scientific, Waltham, MA, USA) for 20 min at room temperature.
Fatty acid methyl esters (FAMEs) were analysed using an Agilent 7890B GC
system coupled to a 7000 Triple Quadrupole GC-MS system, with a Phenomenex
ZB-1701 column (30 m × 0.25 mm × 0.25 μm). An initial temperature of 45 °C
was set to increase at 9 °C min−1, held for 5 min, then 240 °Cmin-1, held for
11.5 min, before reaching a final temperature of 280 °C min−1, held for 2 min.
The instrument was operated in pulsed splitless mode in the electron impact mode,
50 eV, and mass ions were integrated for quantification using known standards to
generate a standard curve. Palmitic, stearic and oleic acid peak areas were extracted
using mass-to-charge ratios (m/z) 270, 298 and 296, respectively. Mass Hunter
B.06.00 software (Agilent) was used to quantify isotopomer peak areas before
natural abundance isotope correction was performed using an in-house algorithm.
Bioinformatics analysis. Gene expression data were downloaded from TCGA and
the GEO website. TCGA RNASeqV2 data were shift log transformed and
GSE21034 data were log transformed, using mean of probes per gene. Expression
values were grouped according to sample type and group distributions were plotted
using the matlab routine boxplot with the bar indicating the median, the box
spanning from the 25th to the 75th percentiles, and whiskers spanning 2.7\sigma.
Outliers beyond that span are indicated in red. Significant difference between the
groups was measured using overall ANOVA.
For survival analysis, gene expression data from human samples (excluding cell
lines) was normalised as before, mean-centred, and clustered into three groups
using k-means. Kaplan–Meier survival curves for the groups were plotted using the
matlab routine kmplot.
Human prostate cancer orthografts. In vivo orthograft experiments were per-
formed in accordance with the ARRIVE guidelines76, and by a local ethics com-
mittee under the Project Licence P5EE22AEE in full compliance with the UK
Home Office regulations (UK Animals (Scientific Procedures) Act 1986). Briefly,
20 × 106 cells/mouse were suspended in serum-free medium and mixed with
Matrigel (Corning, NY, USA) in a 1:1 ratio. 50 µl of cell suspension were injected
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orthotopically into the anterior prostate lobe of CD1-nude mice (Charles River
Laboratories, Wilmington, MA, USA). Orchidectomy was performed at the time of
injection. Tumours were allowed to grow for ~6 weeks after injection and tumour
growth was monitored weekly using a Vevo3100 ultrasound imaging system
(Fujifilm Visualsonics, The Netherlands). At the end of the experiment, mice were
euthanised by excess of CO2 and tumours were collected. Tumour material was
further fixed in 10% formalin for histological procedures or snap-frozen in liquid
nitrogen.
Raman spectroscopy analysis. Raman spectra were acquired on a Renishaw inVia
Raman microscope equipped with a 532 nm Nd:YAG laser giving a maximum
power of 500 mW, 1800 l mm−1 grating, and a Nikon NIR Apo 60×/1.0 N.A. water
dipping objective. Tissue sections were dewaxed immediately prior to Raman
measurements in xylene (2 × 15 min), 100% ethanol (5 min), 95% EtOH (5 min)
and 90% EtOH (5 min). The tissue sections were mapped using a water dipping
objective, using a step size of 100 µm in x and y, with 1 s acquisition time, 100%
laser power and a spectral center of 3000 cm−1.
Renishaw Wire 4.1 was used to perform basic pre-processing steps using the
inbuilt functions in the software. Cosmic rays were removed followed by baseline
subtraction. Baseline was subtracted using the in-built baseline subtraction
intelligent fitting function (with an 11th order polynomial fitting and noise
tolerance set to 1.50 which was applied to the whole spectral dataset). Custom
MATLAB® scripts were then used to perform further analysis. Outlier spectra (high
intensity due to saturation or fluorescence) were removed using a threshold
function. Spectra were cut to between 2800 and 3020 cm−1. Tissue regions were
then selected based on the total spectral intensity for the map and all associated
spectra were extracted and min–max scaled for comparison between conditions.
The resultant spectral data set for each tissue map went through further quality
control steps; firstly, excluding spectra with a total spectral intensity less than
60,000, followed by removing spectra out with one standard deviation of the mean.
Spectra were scaled to the peak at 2933 cm−1, and spectral data sets for all CTL and
DECR1 KO samples were combined, with average for each condition plotted for
comparison. The ratio of the intensities of the peaks at 2845 and 2935 cm−1 was
determined for each spectral data point, as was the ratio of the intensities of the
peaks at 2880 and 2935 cm−1. These values were used to create bar charts depicting
the mean and standard deviation values in GraphPad Prism 7. GraphPad Prism 7
was used to perform a Mann–Whitney test to compare CTL to DECR1 KO for
each ratio.
Patient material and immunohistochemistry. This study was approved by the
West of Scotland Research Ethics Committee (05/S0704/94). All subjects provided
an informed consent and all experiments conformed to the principles set out in the
WMA Declaration of Helsinki and the Department of Health and Human Services
Belmont Report.
Immunohistochemical (IHC) staining for DECR1 was performed on 4 µm
formalin-fixed paraffin-embedded sections which had previously been incubated at
60 °C for 2 h. The IHC staining was performed on an Agilent Autostainer link 48
(Agilent, Santa Clara, CA, USA).
The sections underwent manual dewaxing through xylene, graded alcohol and
then washed in tap water before undergoing heat-induced epitope retrieval (HIER).
HIER was performed on an Agilent PT module where the 4 µm sections were
heated to 98 °C for 25 min in PT module 1 buffer (Thermo Fisher Scientific,
Waltham, MA, USA). After epitope retrieval sections were rinsed in Tris Buffered
saline with Tween (Tbt) prior to being loaded onto the autostainer. The sections
then underwent peroxidase blocking (Agilent, Santa Clara, CA, USA), washed in
Tbt before application of DECR1 antibody (Abcam, Cambridge, UK) at 1/1000
dilution for 40 min. The sections were then washed in Tbt before application of
rabbit EnVision (Agilent, Santa Clara, CA, USA) secondary antibody for 35 min.
Sections were rinsed in Tbt before applying Liquid DAB (Agilent, Santa Clara, CA,
USA) for 10 min. The sections were then washed in water, counterstained with
hematoxylin and mounted using DPX (Thermo Fisher Scientific, Waltham,
MA, USA).
siRNA transfection. Cells were seeded in 6-well plates to reach 70% confluence
and allowed to attach overnight. ON-TARGETplus smartpool siRNAs against
AMPKa (L-005027-00), AR (L-003400-00), DECR1 (L-009642-00-005), as well as
non-targeting siRNA (D-001810-01-20) were purchased from Dharmacon
(Dharmacon, Horizon inspired cell solutions, Cambridge, UK). DECR1 over-
expressing plasmid was purchased from Origene (RC211257, Cambridge
Bioscience, Cambridge, UK). Transfections were performed using Lipofectamine
RNAimax (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) according to
the manufacturer’s protocol.
Generation of DECR1 stable KO cells. DECR1 deletion was performed using the
CRISPR CAS9 gene editing technology. Briefly 1 × 106 cells were transfected with
commercially available DECR1 KO or CTL plasmids (Santa Cruz Technologies,
Dallas, TX, USA) using a nucleofector (Amaxa Biosystems, Lonza, Basel, Swit-
zerland) according to the manufacturer’s instructions. Cells were then cultured in
the presence of 1 µg ml−1 of puromycin (Sigma Aldrich, St Louis, MI, USA) to
allow for clonal selection. Final knock-out of the protein was confirmed using
western blot.
Cell proliferation. 6–8 × 105 cells were seeded in 6-well plates and allowed to
attach for 16 h. The next day, cells were either directly harvested with trypsin (T0)
or allowed to grow for additional 48 or 72 h. Cells were then harvested, suspended
in a defined volume of serum-containing medium and counted using a CASY cell
counter (Roche, Basel, Switzerland). Final cell number was normalised to the initial
cell count obtained at T0.
qPCR analysis. RNA was extracted from cells (70–80% confluence) using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) with on-column DNase digestion
(RNase-Free DNase Set, Qiagen, Hilden, Germany). cDNA was prepared from 4 µg
RNA using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Sci-
entific, Waltham, MA, USA). Real-time PCR was performed using TaqMan Uni-
versal Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) with primer-
appropriate Universal ProbeLibrary probes (Roche, Basel, Switzerland) and the ABI
7500 FAST qPCR system (Thermo Fisher Scientific, Waltham, MA, USA). Gene
expression was normalised to the reference CASC3 gene, and is shown relative to
levels in control cells. A list of the primers (Thermo Fisher Scientific, Waltham,
MA, USA) used in this study is provided in Supplementary Table 1.
Immunoblotting. Cells or crushed frozen tumour tissues were lysed in SDS buffer
(1% SDS supplemented with protease and phosphatase inhibitors) and protein
concentration was determined using the BCA protein assay kit (Thermo Fisher
Scientific, Waltham, MA, USA). Twenty microgram of proteins were then loaded
on to a 4–12% gradient SDS-PAGE gel (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) and transferred to a PVDF membrane (GE Healthcare,
Chicago, IL, USA). Membrane was blocked in 5% milk-TBST for 1 h and probed
overnight with primary antibodies (see Supplementary Table 2) diluted in 5% BSA-
TBST. The membrane was then washed three times with TBST, incubated with
respective HRP-conjugated secondary antibodies diluted in 5% milk-TBST, washed
another three times with TBST and revealed using the ECL kit (GE Healthcare,
Chicago, IL, USA). Images were acquired on a MyECL machine (Thermo Fisher
Scientific, Waltham, MA, USA).
Immunofluorescence. Cells were seeded on coverslips in 24-well plates to reach
50% confluence and allowed to attach overnight. Cells were next fixed in ice-cold
Methanol/Acetone buffer, washed three times with PBS-Tween, blocked for 30 min
in a PBS/BSA (5%) solution and probed with primary antibody overnight (anti AR,
sc-816, Santa Cruz Technologies, Dallas, TX, USA). The next day, coverslips were
washed three times with PBS-Tween, incubated with fluorophore-coupled sec-
ondary antibodies (Abcam, Cambridge, UK) and washed again three times with
PBS. Coverslips were mounted using Diamond Prolong with DAPI (Thermo Fisher
Scientific, Waltham, MA, USA). Pictures were taken on a Nikon A1R confocal
microscope (Nikon Instruments Europe B.V., Amsterdam, The Netherlands).
Chromatin immunoprecipitation (ChIP). Chromatin was prepared with the tru-
ChIP™ Chromatin Shearing Kit (Covaris, Brighton, UK) according to manu-
facturer’s instructions. Each sample was sonicated for 10 min using Covaris
sonicator. ChIP were performed using the IP-Star Compact Automated System
(Diagenode, Liege, Belgium). Briefly, 4 µg of isolated chromatin was immunopre-
cipitated with either 1 µg ChIP grade antibody (anti-AR 17-10489, Millipore
Burlington, MA, USA or anti-AR #5153, Cell Signalling Technology, London, UK)
or 1 µg of IgG (C15410206, Diagenode, Liege, Belgium) in dilution buffer (0.01%
SDS; 1.1% Triton X 100; 2 mM EDTA; 16.7 mM Tris-Cl pH 8.0; 167 mM NaCl; 1×
protease inhibitor cocktail, Sigma Aldrich, St Louis, MI, USA). The DNA/protein
complexes were washed four times in IP Wash buffer (100 mM Tris-HCl pH 8.0;
500 mM LiCl 1%; Triton X100; 1% deoxycholic acid. After reversal of crosslinking,
the immunoprecipitated DNA was purified by a regular DNA extraction protocol
and analysed employing RT-qPCR with the SYBR-Green Takara (Ozyme, Paris,
France) and step one plus applied Real-Time PCR system. The PCR conditions
were 10 min at 95 °C followed by 45 cycles of 10 s at 95 °C, 30 s at 60 °C, and 30 s at
72 °C. The following, primers were used: promoter KLK3 5′ GCC TGG ATC TGA
GAG AGA TAT CAT C 3′ [R] and 5′ ACA CCT TTT TTT TTC TGG ATT GTT G
3′ [F]; and promoter FKBP5 5′ GCA TGG TTT AGG GGT TCT TGC 3′ [R] and 5′
AAC ACC CTG TTC TGA ATG TGG C 3′ [F].
Statistical analysis. Statistical analyses were performed using GraphPad PRISM
software v7.05 (GraphPad Software Inc, San Diego, CA, USA).
Data reproducibility. Figure 1: Panels a, b, f, h: representative image from three
independent biological experiments. Panel c (top): n= 6 independent biological
experiments. Panel c (bottom): n= 55 (LN), 40 (BIC), 51 (APA), 51 (ENZ)
organoids examined over two independent biological experiments. Panels d, e: n=
3 independent biological experiments. Panel g: n= 9 (three independent biological
experiments performed in triplicates).
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Figure 2: Panel b: n= 3 independent biological experiments; Panels c, d, e: n=
3 independent wells from the same cell culture.
Figure 3: Panel a: n= 3 independent wells from the same cell culture. Panel b:
representative image from three independent biological experiments. Panel c: n= 3
independent biological experiments.
Figure 4: Panel a: n= 3 independent wells from the same cell culture. Panel b:
representative image from three independent biological experiments.
Figure 5: Panels b, c, f: representative image from three independent biological
experiments. Panel d: n= 9 (three independent biological experiments performed
in triplicates). Panel e: n= 6 (three independent biological experiments performed
in duplicates). Panel g: n= 14.
Figure 6: Panels a, g, h: representative image from three independent biological
experiments. Panels b, i, j: n= 6 (three independent biological experiments
performed in duplicates). Panels c, d: n= 3 independent biological experiments.
Panels e, f: n= 3 independent wells from the same cell culture.
Figure 7: Panel a: n= 6 mice per group. Panel b: n= 5 mice per group. Panel c:
n= 7203 (CTL), 5425 (KO) peak intensities that were extracted from four mice per
group. Panel d: n= 3 mice per group.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The raw files and the MaxQuant search results files have been deposited as partial
submission to the ProteomeXchange Consortium via the PRIDE partner repository
[Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ,
Inuganti A, Griss J, Mayer G, Eisenacher M, Pérez E, Uszkoreit J, Pfeuffer J, Sachsenberg T,
Yilmaz S, Tiwary S, Cox J, Audain E, Walzer M, Jarnuczak AF, Ternent T, Brazma A,
Vizcaíno JA (2019) The PRIDE database and related tools and resources in 2019:
improving support for quantification data. Nucleic Acids Res 47(D1):D442-D450 (PubMed
ID: 30395289)] with the dataset identifier PXD016836. The following databases were used
in this study: The Cancer Genome Atlas (TCGA—https://tcga-data.nci.nih.gov/tcga/);
GSE21034; STRING v11.0 (https://string-db.org/cgi/input.pl). All the data supporting the
findings of this study are available within the article and its supplementary information
files and from the corresponding author upon reasonable request. A reporting summary
for this article is available as Supplementary Information file. The source data underlying
Figs. 1–7 and Supplementary Figs. 1–6 are provided as a Source data file. Raw data for
lipidomics experiment are provided as Supplementary Data 2.
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